Drug intelligence / Profile preview

NNC9204-0530

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Peptides
Administration: Subcutaneous

Overview

NNC9204-0530 is a long-acting Peptide YY (PYY) analog developed by Novo Nordisk for the treatment of obesity and overweight. It functions as a selective agonist of the Neuropeptide Y receptor Y2 (NPY2R), mimicking the satiety-inducing effects of endogenous PYY3-36. By activating NPY2R in the hypothalamus and other brain regions involved in energy homeostasis, the drug aims to reduce appetite and food intake. NNC9204-0530 is currently being evaluated in Phase 1 clinical trials, both as a monotherapy and in combination with other weight-management agents such as the GLP-1 receptor agonist liraglutide, to explore synergistic effects on weight reduction.

Targets

NPY2R (Neuropeptide Y receptor subtype 2)

Beyond the preview

Go deeper on NNC9204-0530.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC9204-0530.

Explore the full profile